Trial
NCT07408869
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Candid Therapeutics
Collaborators
—
Condition
IgE-Mediated Hypersensitivity
Intervention
Cizutamig
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-22